- 関
- fibrinolytic therapy
WordNet
- (medicine) the act of caring for someone (as by medication or remedial training etc.); "the quarterback is undergoing treatment for a knee injury"; "he tried every treatment the doctors suggested"; "heat therapy gave the best relief"
- a kind of pharmaceutical that can break up clots blocking the flow of blood to the heart muscle (同)thrombolytic_agent, clot buster
PrepTutorEJDIC
- (病気の)治療,療法 / =psychotherapy
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2015/09/15 22:58:37」(JST)
[Wiki en表示]
Thrombolytic drugs are used in medicine to dissolve blood clots in a procedure termed thrombolysis. They limit the damage caused by the blockage or occlusion of a blood vessel.[1]
Contents
- 1 Uses
- 2 Members
- 3 Side-effects
- 4 See also
- 5 References
Uses
Thrombolytic agents are used for the treatment of myocardial infarction (heart attack),[2] thromboembolic strokes, deep vein thrombosis and pulmonary embolism to clear a blocked artery and avoid permanent damage to the perfused (see perfusion) tissue (e.g. myocardium, brain, leg) and death.[3] They may also be used to clear blocked catheters that are used in long-term medical therapy.
Thrombolytic therapy in hemorrhagic strokes is contraindicated, as its use in that situation would prolong bleeding into the intracranial space and cause further damage.
Laboratory findings in various platelet and coagulation disorders (V - T)
Condition |
Prothrombin time |
Partial thromboplastin time |
Bleeding time |
Platelet count |
Vitamin K deficiency or warfarin |
Prolonged |
Normal or mildly prolonged |
Unaffected |
Unaffected |
Disseminated intravascular coagulation |
Prolonged |
Prolonged |
Prolonged |
Decreased |
Von Willebrand disease |
Unaffected |
Prolonged or unaffected |
Prolonged |
Unaffected |
Hemophilia |
Unaffected |
Prolonged |
Unaffected |
Unaffected |
Aspirin |
Unaffected |
Unaffected |
Prolonged |
Unaffected |
Thrombocytopenia |
Unaffected |
Unaffected |
Prolonged |
Decreased |
Liver failure, early |
Prolonged |
Unaffected |
Unaffected |
Unaffected |
Liver failure, end-stage |
Prolonged |
Prolonged |
Prolonged |
Decreased |
Uremia |
Unaffected |
Unaffected |
Prolonged |
Unaffected |
Congenital afibrinogenemia |
Prolonged |
Prolonged |
Prolonged |
Unaffected |
Factor V deficiency |
Prolonged |
Prolonged |
Unaffected |
Unaffected |
Factor X deficiency as seen in amyloid purpura |
Prolonged |
Prolonged |
Unaffected |
Unaffected |
Glanzmann's thrombasthenia |
Unaffected |
Unaffected |
Prolonged |
Unaffected |
Bernard-Soulier syndrome |
Unaffected |
Unaffected |
Prolonged |
Decreased or unaffected |
Factor XII deficiency |
Unaffected |
Prolonged |
Unaffected |
Unaffected |
C1INH deficiency |
Unaffected |
Shortened |
Unaffected |
Unaffected |
Members
The thrombolytic drugs include:
- tissue plasminogen activator t-PA:
-
- alteplase (Activase)
- reteplase (Retavase)
- tenecteplase (TNKase)
- anistreplase (Eminase)
- streptokinase (Kabikinase, Streptase)
- urokinase (Abbokinase)
These drugs are most effective if administered immediately after it has been determined they are clinically appropriate. The advantage of administration is highest within the first sixty minutes after a thrombotic event, but may extend up to six hours after the start of symptoms.
These drugs are often administered in combination with anticoagulant drugs such as intravenous heparin or low molecular weight heparin, for synergistic antithrombotic effects and secondary prevention.
Side-effects
Hemorrhagic stroke is a rare but serious complication of thrombolytic therapy. If a patient has had thrombolysis before, an allergy against the thrombolytic drug may have developed (especially after streptokinase). If the symptoms are mild, the infusion is stopped and the patient is commenced on an antihistamine before infusion is recommenced. Anaphylaxis generally requires immediate cessation of thrombolysis.
See also
- Thrombolysis
- Anticoagulant drugs
- Antiplatelet drugs
References
- ^ "Thrombolytic therapy".
- ^ Ellen C Keeley, Judith A Boura, Cindy L Grines (4 January 2003). "Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials". The Lancet 361: 13–20. doi:10.1016/S0140-6736(03)12113-7. PMID 12517460.
- ^ Selim M. Arcasoy, MD; John W. Kreit (June 1999). "Thrombolytic Therapy of Pulmonary Embolism: A Comprehensive Review of Current Evidence". Chest Journal 115: 1695–1707. doi:10.1378/chest.115.6.1695.
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Predicting stroke evolution: comparison of susceptibility-weighted MR imaging with MR perfusion.
- Kao HW, Tsai FY, Hasso AN.SourceDepartment of Radiological Sciences, University of California at Irvine Medical Center, 101 City Dr. South, Orange, Irvine, CA, 92868, USA.
- European radiology.Eur Radiol.2012 Jul;22(7):1397-403. Epub 2012 Feb 10.
- OBJECTIVES: To investigate the ability of susceptibility-weighted imaging (SWI) to predict stroke evolution in comparison with perfusion-weighted imaging (PWI).METHODS: In a retrospective analysis of 15 patients with non-lacunar ischaemic stroke studied no later than 24 h after symptom onset, we us
- PMID 22322311
- Novel multi-functional nitrones for treatment of ischemic stroke.
- Sun Y, Zhang G, Zhang Z, Yu P, Zhong H, Du J, Wang Y.SourceInstitute of New Drug Research and Guangdong Province Key Laboratory of Pharmacodynamic Constituents of Traditional Chinese Medicine, Jinan University College of Pharmacy, Guangzhou 510632, China.
- Bioorganic & medicinal chemistry.Bioorg Med Chem.2012 Jun 15;20(12):3939-45. Epub 2012 Apr 21.
- Ischemic stroke resulting from obstruction of blood vessels is an enormous public health problem with urgent need for effective therapy. The co-administration of thrombolytic/antiplatelet agent and neuroprotective agent improves therapeutic efficacy and agent possessing both thrombolytic/antiplatele
- PMID 22579617
Japanese Journal
- 症例報告 経静脈的および経動脈的に血行再建術をおこなった心臓粘液腫による脳塞栓症の1例
- 神谷 雄己,市川 博雄,水間 啓太 [他]
- 臨床神経学 = Clinical neurology 54(6), 502-506, 2014-06
- NAID 40020121686
- Purification and characterization of a novel fibrinolytic α chymotrypsin like serine metalloprotease from the edible mushroom, Lyophyllum shimeji(ENZYMOLOGY, PROTEIN ENGINEERING, AND ENZYME TECHNOLOGY)
- Moon Sung-Min,Kim Jae-Sung,Kim Heung-Joong [他],Choi Mi Suk,Park Bo Ram,Kim Su-Gwan,Ahn Hoon,Chun Hong Sung,Shin Yong Kook,Kim Jong-Jin,Kim Do Kyung,Lee Sook-Young,Seo Young-Woo,Kim Yong Hwan,Kim Chun Sung
- Journal of bioscience and bioengineering 117(5), 544-550, 2014-05
- … shimeji, might be useful for thrombolytic therapy and preventing thrombotic disease. …
- NAID 110009823128
- 保存的治療後の上腸間膜静脈血栓症に合併した遅発性小腸狭窄に対して内視鏡的拡張術が奏功した1例
- 方堂 祐治,守護 晴彦,米島 學
- 日本消化器内視鏡学会雑誌 56(6), 1980-1985, 2014
- 症例は62歳,男性.B型慢性肝炎にて内服治療中に腹痛を自覚し,腹部CTにて上腸間膜静脈血栓症と診断した.保存的に抗凝固,血栓溶解療法を施行し血栓症は改善したが,発症75日後に小腸狭窄による腸閉塞をきたした.腹部CTにて空腸に限局する長さ2cm程度の狭窄を認めたため,小腸シングルバルーン内視鏡にて狭窄部を観察し,内視鏡的バルーン拡張術を施行した.その後は1年以上狭窄症状なく経過している.上腸間膜静脈 …
- NAID 130004555338
Related Links
- Thrombolytic therapy is the use of drugs to break up or dissolve blood clots, which are the main cause of both heart attacks and stroke. ... Thrombolytic medications are approved for the immediate treatment of stroke and ...
- What is thrombolytic therapy? Thrombolytic therapy is a treatment used to break up dangerous clots inside your blood vessels. To perform this treatment, your physician injects clot-dissolving medications into a blood vessel. In some ...
Related Pictures
★リンクテーブル★
[★]
- 英
- thrombolytic therapy, thrombolysis
- 関
- 血栓
[★]
- 英
- thrombolytic therapy
- 関
- 線溶療法
[★]
線溶療法
- 関
- thrombolytic therapy
[★]
経静脈的血栓溶解療法
[★]
- 関
- care、cure、curing、practice、psychotherapy、regimen、remediation、remedy、therapeutic、treat、treatment、treatment protocol
[★]
- 関
- fibrinolytic agent、thrombolysis、thrombolytic agent、thrombolytic drug、thrombolytics
[★]
血栓溶解薬
- 関
- fibrinolytic agent、thrombolytic、thrombolytic drug